Nuvectis Pharma, Inc.
NVCT · XNASCIK 1875558fmd_0WCD5HD8QB3SDMPX2HEZNRWTN9Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2021 to Sep 30, 2026, 23 periods
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Research and development | 10 | 13 | 15 | 13 | 18 |
| Compensation and benefits | 0 | 2 | 2 | 2 | 2 |
| Operating income | (13) | (19) | (23) | (20) | (28) |
| Net income | (13) | (19) | (22) | (19) | (26) |
| Net income to common shareholders | (13) | (19) | (22) | (19) | (29) |